Transcenta Therapeutics says it will grant WuXi Biologics and its affiliates a non-exclusive license to certain technologies relating to Transcenta’s intensified continuous bioprocessing (HiCB) platform and ExcelPro cell culture media.
Transcenta will receive an upfront payment of $1.5 million and will be eligible for milestone payments upon the achievement of specified conditions. Through this collaboration, WuXi Biologics will become Transcenta’s strategic partner for CMC development and supporting molecules across Transcenta’s development pipeline.
A Transcenta spokesperson explained that the HiCB platform integrates intensified continuous perfusion upstream processing with hybrid continuous downstream purification, enabling a step-change in productivity, achieving an increase in productivity compared with conventional fed-batch processes.
HiCB can significantly reduce cost of goods, lower capital investment, and enable agile production, claims the company official, while providing a solution for improving recovering yield and product quality for complex biologics.
Transcenta, headquartered in Suzhou, China, is a clinical-stage biopharmaceutical company with expertise in biologics discovery, translational research, clinical, and process development. The company develops a pipeline of over ten therapeutic antibody candidates spanning oncology, bone, and kidney disorders.
